Xeris Biopharma (NASDAQ:XERS) Stock Price Down 3.5%

Posted by Defense World Staff on Apr 26th, 2023

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Rating)’s stock price fell 3.5% on Tuesday . The stock traded as low as $2.19 and last traded at $2.21. 942,582 shares changed hands during trading, a decline of 25% from the average session volume of 1,249,642 shares. The stock had previously closed at $2.29.

Wall Street Analyst Weigh In

Several research firms recently weighed in on XERS. SVB Leerink reduced their target price on shares of Xeris Biopharma from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, January 27th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a research report on Thursday, March 9th.

Xeris Biopharma Trading Down 3.5 %

The company has a current ratio of 2.54, a quick ratio of 2.20 and a debt-to-equity ratio of 4.14. The business’s 50-day simple moving average is $1.59 and its two-hundred day simple moving average is $1.42. The company has a market capitalization of $299.52 million and a PE ratio of -3.16.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently modified their holdings of the stock. Deltec Asset Management LLC lifted its position in shares of Xeris Biopharma by 68.6% during the first quarter. Deltec Asset Management LLC now owns 622,072 shares of the company’s stock worth $1,014,000 after purchasing an additional 253,146 shares during the last quarter. Alliancebernstein L.P. lifted its position in shares of Xeris Biopharma by 63.5% during the fourth quarter. Alliancebernstein L.P. now owns 39,400 shares of the company’s stock worth $52,000 after purchasing an additional 15,300 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Xeris Biopharma by 54.4% during the fourth quarter. Jane Street Group LLC now owns 181,562 shares of the company’s stock worth $241,000 after purchasing an additional 63,964 shares during the last quarter. Millennium Management LLC bought a new position in shares of Xeris Biopharma during the fourth quarter worth about $923,000. Finally, AQR Capital Management LLC lifted its position in shares of Xeris Biopharma by 144.6% during the fourth quarter. AQR Capital Management LLC now owns 50,254 shares of the company’s stock worth $67,000 after purchasing an additional 29,712 shares during the last quarter. Institutional investors own 0.12% of the company’s stock.

Xeris Biopharma Company Profile

(Get Rating)

Xeris Biopharma Holdings, Inc is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing’s syndrome.